# US 2001/0027247 A1 · Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0027247 A1
- Document ID: US20010027247A1
- Status: Published application
- Kind: A1
- Application number: 09/793,676
- Filed: 2001-02-26
- Published: 2001-10-04
- Earliest claimed: 1995-06-07
- Assignees: G.D. Searle & Co.
- Inventors: Gunnar J. Hanson
- Web page: https://patentgrep.com/patent/US20010027247A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- C07K 7/02: Linear peptides containing at least one abnormal peptide link
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Non-peptidic compounds characterized by containing a segment condensed from pipecolic acid, aspartic acid, proline and threonine, or derivatives thereof, are useful to treat autoimmune diseases and inflammatory conditions. Compounds of particular interest are those of the formula: 1 wherein R1 is phenyl or cyclohexyl; wherein R2 is hydrido or methyl; wherein R3 is selected from hydrido, hydroxy, acetylamino, acetyl(Lys/Tyr/Thr)NH—, propionylamino and benzyloxycarbonylamino; wherein R5 is selected from isopropyl, isobutyl, n-propyl, n-butyl, aminopropyl, aminobutyl, phenyl, benzyl, hydroxyphenyl, hydroxybenzyl, morpholinocarbonylethyl, morpholinocarbonylpropyl, piperazinocarbonylethyl, piperazinocarbonylpropyl, pyridinylcarbonylethyl, pyridinylcarbonylpropyl, oxazolylcarbonylethyl, oxazolylcarbonylpropyl, azepinylcarbonylethyl and azepinylcarbonylethyl; wherein R6 is selected from hydrido, methyl, hydroxy, methoxy, phenyl and aminocarbonyl; wherein R7 is carboxyl or methylthiomethyl; wherein R9 is selected from hydrido, hydroxy, methoxy and phenyl; wherein R12 is selected from methyl, ethyl, propyl, butyl, isobutyl, —CH(iBu)CH2OH and —CH(iBu)CONH2; or a pharmaceutically-acceptable amide, ester or salt thereof. A disease state of particular interest for use of the compounds would be rheumatoid arthritis.

## Claims

### Claim 1

A compound of Formula I: 74
wherein R1 is selected from alkyl, phenyl, cycloalkyl rings having four to ten ring-member carbon atoms, bicycloalkyl fused ring systems having seven to nine ring-member carbon atoms, heteroaryl, heteroarylalkyl, benzo-fused-heteroaryl and benzo-fused-heteroarylalkyl wherein said heteroaryl moiety or fragment is a 5- or 6-ring-member fully-unsaturated ring system having one hetero atom as a ring member, said hetero atom selected from oxygen, nitrogen and sulfur atoms, and wherein any of said heteroaryl, heteroarylalkyl, benzo-fused-heteroaryl and benzo-fused-heteroarylalkyl may be attached to the nucleus of Formula I as an R1 substituent through a bond formed at any said ring-member atom or any atom of the alkyl portion of said R1 substituent where said bond is capable of forming a stable compound;
wherein R2 is selected from hydrido, lower alkyl, cyclohexyl and phenyl;
wherein R3 is selected from hydrido, hydroxy, lower alkyl, phenyl, acetyl(Lys)NH—, acetyl(Tyr)NH—, acetyl(Thr)NH—, acetylamino, propionylamino and benzyloxycarbonylamino;
wherein R4 is selected from hydrido, lower alkyl and phenyl;
wherein R5 is selected from hydrido, lower alkyl, phenyl, benzyl, hydroxyphenyl, hydroxybenzyl, aminoalkyl, mono-alkyl-substituted-aminoalkyl and radicals provided by B-Het-A;
wherein Het is selected from heteroaryl moieties consisting of monocyclic and fused bicyclic ring systems having a total of five to fourteen ring members and with one to six ring members being selected from hetero atoms provided by oxygen, nitrogen and sulfur atoms, wherein said monocyclic ring system and at least one ring system of said fused bicyclic ring system is fully unsaturated, and
wherein Het is further selected from heterocyclic moieties consisting of monocyclic and fused polycyclic ring systems having a total of four to twelve ring members and with one to six ring members selected from hetero atoms provided by oxygen, nitrogen and sulfur atoms, wherein said monocyclic ring-system and at least one ring system of said fused polycyclic ring system is fully saturated or partially unsaturated,
wherein A is a single covalent bond or is a divalent radical selected from 75
wherein R13 is lower alkyl;
wherein B is one or more substituents attached at a substitutable position on Het of Het-A, said substituent selected from hydrido, hydroxy, alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, carboxy, alkenyl, alkynyl, halo, haloalkyl, oxo, cyano, benzyl and phenyl;
wherein R6 is selected from hydrido, lower alkyl, hydroxy, alkoxy, alkoxyalkyl, carboxyalkyl, alkoxycarbonyl, alkoxycarbonyloxy, aminoalkyl, mono-alkyl-substituted-aminoalkyl, amido and amidoalkyl;
wherein R7 is selected from carboxyl, lower alkyl, amido and methylthiomethyl;
wherein R8 is selected from hydrido, methyl and ethyl;
wherein R9 is selected from hydrido, lower alkyl, alkoxy and phenyl;
wherein R10 is hydrido or hydroxy;
wherein R11 is hydrido or methyl;
wherein R12 is selected from lower alkyl, phenyl, phenylalkyl, cycloalkyl, cycloalkylalkyl, 76
wherein each of R14 through R17 is independently selected from hydrido, hydroxy, alkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, halo, haloalkyl, cyano, benzyl and phenyl;
wherein each of R18 and R19 is independently selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, benzyl and phenyl;
or a pharmaceutically-acceptable amide, ester or salt thereof.

### Claim 2 (depends on 1)

Compound of claim 1 wherein R1 is selected from cyclopentyl, cyclohexyl, cycloheptyl, norbornanyl, phenyl, furyl, pyrrolyl, thienyl, chromanyl, isochromanyl, benzothienyl, pyridyl, indolizinyl, isoindolyl, indolyl, 3H-indolyl, quinolizinyl, quinolyl, isoquinolyl, azetidinyl, thioazetidinyl, pyrrolidinyl, pyrrolinyl, oxazolidinyl,thiazolidinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidinyl, piperazinyl, 1,3-morpholino, 1,4-morpholino, 1,4-thiomorpholino, azepinyl, oxazopinyl, thiazopinyl, oxazocinyl, thiazocinyl, azoninyl, oxazabicyclo, benzo-fused-oxazolidinyl, benzo-fused-thiazolidinyl, benzo-fused-morpholino, benzo-fused thiomorpholinyl, benzo-fused-thiazopinyl, benzo-fused oxazopinyl, benzo-fused-oxazocinyl, benzo-fused-oxazoninyl, tropanyl and benzo-fused-oxazobicyclo;
wherein R2 is selected from hydrido, methyl, ethyl, propyl, cyclohexyl and phenyl;
wherein R3 is selected from hydrido, hydroxy, methyl, ethyl, phenyl, acetyl(Lys)NH—, acetyl(Tyr)NH—, acetyl(Thr)NH—, acetylamino, propionylamino and benzyloxycarbonylamino;
wherein R4 is hydrido or methyl;
wherein R5 is selected from hydrido, n-propyl, isopropyl, n-butyl, isobutyl, phenyl, benzyl, hydroxyphenyl, hydroxybenzyl, aminopropyl, aminobutyl and radicals provided by B-Het-R13 and 77
wherein Het is selected from furyl, pyrrolyl, thienyl, chromanyl, isochromanyl, benzothienyl, pyridyl, indolizinyl, isoindolyl, indolyl, 3H-indolyl, quinolizinyl, quinolyl, isoquinolyl, imidazolyl, pyrazolyl, oxazolidyl, thiazolidyl, isothiazolidyl, isoxazolidyl, furazanyl, pyrazinyl, pyrimidinyl, pyridazinyl, indazolyl, purinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, thieno-furanyl, furopyranyl, pyrido-oxazinyl, pyrazolo-oxazolyl, imidazo-thiazolyl, pyrazino-pyridazinyl, imidazo-thiazolyl, oxothiolo-pyrrolyl, imidazo-triazinyl, benzoxazinyl, azetidinyl, thioazetidinyl, pyrrolidinyl, pyrrolinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidinyl, piperazinyl, 1,3-morpholino, 1,4-morpholino, 1,4-thiomorpholino, azepinyl, oxazopinyl, thiazopinyl, oxazocinyl, thiazocinyl, azoninyl, oxazabicyclo, benzo-fused-oxazolidinyl, benzo-fused-thiazolidinyl, benzo-fused-morpholino, benzo-fused thiomorpholinyl, benzo-fused-thiazopinyl, benzo-fused oxazopinyl, benzo-fused-oxazocinyl, benzo-fused-oxazoninyl, tropanyl and benzo-fused-oxazobicyclo;
wherein R13 is lower alkyl;
wherein B is one or more substituents attached at a substitutable position on Het, said substituent selected from hydrido, hydroxy, alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, oxo, benzyl and phenyl;
wherein R6 is selected from hydrido, lower alkyl, hydroxy, methoxy carboxyalkyl, alkoxycarbonyl, alkoxycarbonyloxy, aminoalkyl, mono-alkyl-substituted-aminoalkyl, amido and amidoalkyl;
wherein R7 is selected from carboxyl, lower alkyl, amido and methylthiomethyl;
wherein R8 is hydrido or methyl;
wherein R9 is selected from hydrido, lower alkyl, methoxy and phenyl;
wherein R10 is hydrido or hydroxy;
wherein R11 is hydrido or methyl;
wherein R12 is selected from lower alkyl, phenyl, benzyl, phenylethyl, cyclohexylethyl, 78
wherein each of R14 through R17 is independently selected from hydrido, hydroxy and alkyl;
or a pharmaceutically-acceptable amide, ester or salt thereof.

### Claim 3 (depends on 2)

Compound of claim 2 wherein R1 is selected from cyclopentyl, cyclohexyl, cycloheptyl, norbornanyl, phenyl, azetidinyl, thioazetidinyl, pyrrolidinyl, pyrrolinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidinyl, piperazinyl 1,3-morpholino, 1,4-morpholino, 1,4-thiomorpholino, azepinyl, oxazopinyl, thiazopinyl, oxazocinyl, thiazocinyl, azoninyl, oxazabicyclo and tropanyl;
wherein R2 is selected from hydrido, methyl, ethyl, propyl, acetyl(Lys)NH—, acetyl(Tyr)NH—, acetyl(Thr)NH—, cyclohexyl and phenyl;
wherein R3 is selected from hydrido, hydroxy, methyl, ethyl, phenyl, acetylamino, propionylamino and benzyloxycarbonylamino;
wherein R4 is hydrido or methyl;
wherein R5 is selected from hydrido, n-propyl, isopropyl, n-butyl, isobutyl, aminopropyl, aminobutyl, phenyl, hydroxyphenyl, benzyl, hydroxybenzyl and radicals provided by 79
wherein Het is selected from azetidinyl, pyridinyl, isoindolyl, oxazolyl, isoxazolyl, indolyl, quinolyl, isoquinolyl, azetidinyl, thioazetidinyl, pyrrolidinyl, pyrrolinyl, oxazolidinyl, thiazolidinyl, imidazolyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidinyl, piperazinyl, 1,3-morpholino, 1,4-morpholino, 1,4-thiomorpholino, azepinyl, oxazopinyl, thiazopinyl, oxazocinyl, thiazocinyl, azoninyl, oxazabicyclo and tropanyl;
wherein R13 is selected from methyl, ethyl and propyl;
wherein B is one or more substituents attached at a substitutable position on Het, said substituent selected from hydrido, hydroxy, methyl, ethyl, propyl, oxo, benzyl and phenyl;
wherein R6 is selected from hydrido, methyl, hydroxy, methoxy, phenyl, alkoxycarbonyl, alkoxycarbonyloxy, aminoalkyl, mono-amido and amidoalkyl;
wherein R7 is selected from carboxyl, n-propyl, n-butyl, amido and methylthiomethyl;
wherein R8 is hydrido or methyl;
wherein R9 is selected from hydrido, lower alkyl, methoxy and phenyl;
wherein R10 is hydroxy;
wherein R11 is hydrido or methyl;
wherein R12 is selected from lower alkyl, phenyl, phenylethyl, cyclohexylethyl, 80
wherein each of R14 through R17 is independently selected from hydrido, hydroxy, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, benzyl and phenyl;
or a pharmaceutically-acceptable amide, ester or salt thereof.

### Claim 4 (depends on 3)

Compound of claim 3 wherein R1 is phenyl or cyclohexyl; wherein R2 is hydrido or methyl; wherein R3 is selected from hydrido, hydroxy, acetyl(Lys)NH—, acetyl(Tyr)NH—, acetyl(Thr)NH—, acetylamino, propionylamino and benzyloxycarbonylamino; wherein R4 is hydrido; wherein R5 is selected from isopropyl, isobutyl, n-propyl, n-butyl, aminopropyl, aminobutyl, phenyl, benzyl, para-hydroxyphenyl, para-hydroxybenzyl, imidazolcarbonylethyl, imidazolcarbonylpropyl, pyrrolidinylcarbonylethyl, pyrrolidinylcarbonylpropyl, azetidinylcarbonylethyl, azetidinylcarbonylpropyl, morpholinocarbonylethyl, morpholinocarbonylpropyl, piperazinocarbonylethyl, piperazinocarbonylpropyl, pyridinylcarbonylethyl, pyridinylcarbonylpropyl, oxazolylcarbonylethyl, oxazolylcarbonylpropyl, isoxazolylcarbonylethyl, isoxazolylcarbonylpropyl, azepinylcarbonylethyl and azepinylcarbonylethyl; wherein R6 is selected from hydrido, methyl, hydroxy, methoxy, phenyl and aminocarbonyl; wherein R7 is carboxyl or methylthiomethyl; wherein R8 is hydrido; wherein R9 is selected from hydrido, hydroxy, methyl, methoxy and phenyl; wherein R10 is hydroxy; wherein R11 is methyl; wherein R12 is selected from methyl, ethyl, propyl, butyl, isobutyl, —CH(iBu)CH2OH and —CH(iBu)CONH2; or a pharmaceutically-acceptable amide, ester or salt thereof.

### Claim 5 (depends on 4)

Compound of claim 4 which is 81

### Claim 6 (depends on 4)

Compound of claim 4 which is 82

### Claim 7 (depends on 4)

Compound of claim 4 which is 83

### Claim 8 (depends on 4)

Compound of claim 4 which is 84
